The orphan drug industry is gaining importance as a significant and rewarding market in the pharmaceutical and biotech sectors. Technological and scientific innovations in specific drug discovery pathways as well as major developments in genetics are cultivating growth in this industry. The objective in conducting this report is to provide detailed information on drug development in rare diseases. This report provides a comprehensive analysis and examines the future direction of these drugs as an important means for the treatment of orphan and rare diseases.
Request Free Sample Report at https://www.wiseguyreports.com/sample-request/6190824-drug-development-in-rare-diseases-focus-on-clinical
ASTELLAS PHARMA INC.
EISAI CO. LTD.
ELI LILLY AND CO.
- HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO.
TAKEDA PHARMACEUTICALS LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
This report analyzes the regulatory framework for the clinical trials of orphan drugs in rare and orphan diseases. The report also analyzes the trends and characteristics of clinical trials conducted on rare diseases from 1999-2018, using information from various sources. This report covers an overview of the global orphan drugs market and its competitive landscape.
– An overview of the drug development in rare diseases with special focus on clinical trial and regulatory landscape
– Detailed description of different kinds of orphan drugs and a comparative assessment on biological and chemical or non-biological orphan drugs
– Discussion on Orphan Drug Act; insights into general framework for the regulation of drugs and biologics, and regulations for clinical trials of orphan designated drugs
– H-ighlights of technological advances and innovations in genetic manufacturing technologies and information on terms such as generic competition, patent expirations, premium pricing and information on orphan drug designation applications
Table of Content
Chapter 1 Introduction
Chapter 2 Definitions and Background
Chapter 3 FDA Regulation of Clinical Trials on Orphan Designated Drugs
Chapter 4 European Regulation of Clinical Trials on Orphan Designated Drugs
Chapter 5 Asian Regulation of Clinical Trials on Orphan Designated Drugs
Chapter 6 Trends in Clinical Trials for Drug Development in Rare Diseases
Chapter 7 Competitive Landscape and Global Markets
Chapter 8 Current Trends
Chapter 9 Company Profiles
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)